News
Novartis and the NHS sign ‘landmark’ deal for cholesterol drug
A new agreement between Novartis and the NHS will enable “broad and rapid” access to cholesterol-lowering medicine Leqvio (inclisiran) for patients with long-term elevated LDL cholesterol (LDL-C), which is a known cause of atherosclerotic cardiovascular disease (ASCVD).